


*Supplementary material*

---

*Patoulas D, Toumpourleka M, Katsimardiu A, et al. Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiol Pol. 2022.*

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.



**Figure S1**

**Table S1.** Participants' baseline characteristics of interest

<b>Baseline characteristic</b>	<b>Value</b>
<b>Enrolled subjects</b>	20
<b>Male</b>	15 (75%)
<b>Age, in years</b>	62.8 (7.87)
<b>Body weight, in kg</b>	90.5 (15.98)
<b>Body mass index, in kg/m<sup>2</sup></b>	31.31 (5.59)
<b>Glycated haemoglobin, %</b>	7.42 (1.76)
<b>Type 2 diabetes mellitus duration, in years</b>	9.5 (4.5–12.25) <sup>†</sup>
<b>Arterial hypertension</b>	15 (75%)
<b>Dyslipidemia</b>	11 (55%)
<b>Cardiovascular disease</b>	12 (60%)
<b>Coronary artery disease</b>	8 (40%)
<b>Heart failure</b>	1 (5%)
<b>Atrial fibrillation</b>	0
<b>Cerebrovascular disease</b>	4 (20%)
<b>Peripheral artery disease</b>	1 (5%)
<b>Chronic kidney disease</b>	1 (5%)
<b>Chronic obstructive pulmonary disease</b>	3 (15%)
<b>Obstructive sleep apnea</b>	4 (20%)

\*Data is presented as mean (standard deviation) or as absolute number (relative frequency), unless otherwise stated.

<sup>†</sup> Data is presented as median (interquartile range) value, due to non-normal distribution.

**Table S2.** Participants' drug treatment prior to enrollment in the study

<b>Drug or drug class</b>	<b>Number of participants (relative frequency)</b>
<b>Insulin</b>	5 (25%)
<b>Metformin</b>	19 (95%)
<b>Glucagon-like peptide-1 receptor agonists</b>	4 (20%)
<b>Dipeptidyl-peptidase-4 inhibitors</b>	11 (55%)
<b>Pioglitazone</b>	0
<b>Sulphonylureas</b>	3 (15%)
<b>Renin-angiotensin-aldosterone system blockers</b>	15 (75%)
<b>Calcium channel blockers</b>	3 (15%)
<b>Diuretics</b>	10 (50%)
<b>B-blockers</b>	9 (45%)
<b>Antiplatelet agents</b>	13 (65%)
<b>Statins</b>	14 (70%)

**Table S3.** Effect of SGLT-2 inhibitors on major prespecified echocardiographic parameters

Echocardiographic parameter	Baseline	Follow-up	<i>P</i> -value
RV diameter base (mm)	33.55 (2.96)	32.35 (4.29)	0.94
RV diameter mid (mm)	28.35 (2.03)	27.1 (3.42)	0.94
RV End-diastolic area (cm <sup>2</sup> )	16.64 (2.96)	15.62 (3.23)	0.91
RV End-systolic area (cm <sup>2</sup> )	10.75 (2.4)	10.54 (2.24)	0.68
TAPSE (cm)	2.01 (0.23)	2.12 (0.15)	<b>0.02<sup>†</sup></b>
RV s' (cm/s)	12.55 (3.53)	11.7 (2.18)	0.82
RV e' (cm/s)	9 (2.58)	8.85 (2.52)	0.41
RV a' (cm/s)	15.1 (4.12)	14 (2.71)	0.9
RV e'/a'	0.61 (0.19)	0.62 (0.17)	0.44
RA major axis (mm)	49.20 (5.16)	46.50 (4.87)	0.97
RA minor axis (mm)	33.35 (7.45)	31.80 (4.20)	0.61
RA area (cm <sup>2</sup> )	13.73 (3.08)	12.64 (2.66)	0.95
RVSP (mm Hg)	24.10 (5.34)	22.40 (5.06)	0.98
Tv reg max (m/s)	2.26 (0.3)	2.18 (0.28)	0.88
RA EF (%)	41.81 (13.8)	46.52 (17.97)	0.15

\*Data is presented as mean  $\pm$  standard deviation, unless otherwise stated.

\*\*Abbreviations: RV: right ventricular; RA: right atrial; RVSP: right ventricular systolic pressure; EF: ejection fraction; Tv reg: tricuspid valve regurgitation jet velocity; TAPSE: tricuspid annular plane systolic